Zydus’ generic of hormone therapy patch gets U.S. FDA nod
The product is eligible for the 180-day exclusivity period available to certain first approved applicants under the CGT pathway, subject to the provisions of the U.S.
Federal Food, Drug, and Cosmetic Act.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.thehindu.com — the content belongs to The Hindu.
